Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00159445
Status:
COMPLETED
Last Update Posted:
2014-05-22
First Post:
2005-09-07
Brief Title:
Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
Phase II Study of Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is for patients with colorectal cancer that has spread and has increased in size after standard treatments This study is being done to find out how long it takes their tumors to grow after treatment with the chemotherapy drugs capecitabine and gemcitabine Capecitabine is a chemotherapy drug that has been approved by the FDA for the treatment of colorectal cancer We are adding another drug called gemcitabine which is approved by the FDA for the treatment of cancer of the pancreas to see if the ability of capecitabine to shrink tumors can be improved by adding gemcitabine The side effects of the combination will also be evaluated Another purpose of this study is to measure the levels of certain substances that affect how the body reacts to the chemotherapy agents in cancer cells in the tumor In addition the genes which are the cells blueprint for these substances will also be evaluated in the blood
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None